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Abstract
Neuroblastoma, originated from neural crest cells, is the most common extra-
cranial solid tumor in childhood. Treatment is of limited utility for high-risk 
neuroblastoma and prognosis is poor. The high incidence of resistance of advanced-
stage neuroblastoma to conventional therapies has prompt investigators to search 
for novel therapeutic approaches. Activation of IGF-R/PI3K/Akt/mTOR signaling 
pathway correlates with oncogenesis, poor prognosis, and chemotherapy resistance 
in neuroblastoma. Therefore, we investigated the effect of IGF-R/PI3K/Akt/mTOR 
signaling inhibitors in neuroblastoma. Significantly, IGF-R/PI3K/Akt/mTOR 
signaling inhibitors effectively inhibited cell growth and induced cell cycle arrest, 
autophagy, and apoptosis in neuroblastoma cells. Moreover, IGF-R/PI3K/Akt/
mTOR signaling inhibitors significantly reduced tumor growth in mice xenograft 
model without apparent toxicity. Therefore, these results highlight the potential of 
IGF-R/PI3K/Akt/mTOR signaling pathway as a promising target for neuroblastoma 
treatment. Therefore, IGF-1R/PI3K/Akt/mTOR signaling inhibitors should be 
further investigated for treatment in clinical trials for high-risk neuroblastoma.
Keywords: neuroblastoma, insulin-like growth factor (IGF), phosphatidylinositol 
3-kinase (PI3K), protein kinase-B (Akt), mammalian target of rapamycin (mTOR)
1. Introduction
Neuroblastoma (NB) is one of the most common extracranial solid tumors 
of early childhood [1, 2]. Prognosis of patients with NB depends on tumor stage, 
patient’s age, and biologic feature of the tumor cells [3]. In patients under 1 year 
of age, NB is curable and sometimes spontaneously regress [4]. However, in older 
children with advanced stage, often the tumor is very aggressive, and patients 
have poor prognosis despite treatment with high-dose chemotherapy combined 
with autologous hematopoietic stem cell transplantation. Although immunothera-
peutic therapy such as anti-GD2 monoclonal antibody has improved outcomes of 
advanced stage of NB, a number of patients still relapse and eventually die of dis-
ease [5]. The high incidence of resistance of high-risk NB to conventional therapies 
has prompted us to search for novel therapeutic approaches.
It was reported that phosphorylated protein kinase-B (Akt) correlates with poor 
patients’ prognosis in NB [6], and the phosphatidylinositol-3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway has subsequently been linked 
to augmented cell survival [7] and increased resistance to chemotherapy in NB [8]. 
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Therefore, targeting the PI3K/Akt/mTOR signaling pathway by appropriate inhibi-
tors appears to be a promising strategy for overcoming therapy resistance [9].
Here, we demonstrate that NB cell lines are heterogeneous in their insulin 
growth factor-1 (IGF-1) receptor-mediated signaling [10]. The pattern of IGF-1 
receptor/PI3K/Akt/mTOR pathway-mediated proliferation is an important deter-
minant of the response to IGF-1 receptor antagonistic therapy in human NB [10]. 
Furthermore, our results highlight the potential of IGF-1 receptor/PI3K/Akt/mTOR 
signaling pathway as a promising target for NB treatment [10–13].
2.  Heterogeneity of IGF-1 receptor/Akt pathway-mediated proliferation 
in NB
IGF-1, IGF-2, and insulin belong to a family of mitogenic growth factors and 
are involved in normal growth and differentiation of most tissues. The biological 
actions of both IGFs and insulin can be mediated by the IGF-1 receptor which 
is involved in mitogenic, anti-apoptotic, and oncogenic transforming responses 
[14, 15]. The IGF-1 receptor has two extracellular α-subunits and two intracel-
lular β-subunits that form a heterotetrameric complex. Ligand interaction with 
α-subunits triggers the autophosphorylation of tyrosine kinase domains within the 
β-subunit [16–18]. The tyrosine kinase domains are connected to several intracel-
lular pathways such as PI3K/Akt [19, 20]. Dysregulation of the IGF-1 receptor 
pathway is involved in promoting oncogenic transformation, cell proliferation, 
metastasis, angiogenesis, and resistance in numerous malignant diseases, such 
as multiple myeloma [21], carcinomas [22], and NB [23]. Since high cellular het-
erogeneity is a hallmark of NB, which may account for the wide range of clinical 
presentations and nonuniform response to treatment, we hypothesized that NB 
cells are heterogeneous in their IGF-1 receptor signaling-mediated cell prolifera-
tion. Thirty-one NB cell lines were cultured in three different conditions, insulin-
containing serum-free medium (SFM), RPMI1640 without FBS (serum starvation 
medium), and RPMI1640 with 10% FBS (serum-containing medium). Based on 
the response patterns, 31 cell lines were subdivided into three groups [10]. Group 1, 
which consisted of three NB cell lines, could proliferate for more than 3 days in 
SFM, RPMI1640 without FBS, and RPMI1640 with 10% FBS [10]. Group 2, which 
consisted of 10 cell lines, could proliferate in SFM and RPMI1640 with 10% FBS 
but not in RPMI1640 [10]. Group 3, which consisted of 18 NB cell lines, proliferated 
only in RPMI1640 with 10% FBS [10]. NB cell proliferation in RPMI1640 in the 
presence of exogenous IGF (IGF-1, IGF-2) and insulin was examined. These IGF 
and insulin accelerated cell proliferation in group 1 and group 2 NB cell lines but 
not in group 3 NB cell lines [10]. Group 1 NB cell lines were able to proliferate in 
RPMI1640 in the absence of exogenous IGF and insulin [10].
3.  Impairment of Akt activation and cell proliferation in NB by IGF-1 
receptor inhibitor, picropodophyllin (PPP)
The IGF-1 receptor inhibitors, such as IGF-1 receptor-neutralizing antibodies and 
IGF-1 receptor antisense/siRNA, have been shown to block cancer cell proliferation 
[24]. Selective IGF-1 receptor inhibitor, picropodophyllin (PPP), lacks inhibitory 
activity on tyrosine phosphorylation of insulin receptor tyrosine kinase (RTK) [25]. 
Inhibition of the IGF-1 RTK with PPP is noncompetitive with respect to ATP, sug-
gesting interference with the IGF-1 receptor at substrate level [26]. It is reported that 
PPP specifically blocks phosphorylation of the Tyr1136 residue in the activation loop 
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of IGF-1 receptor kinase [27]. Inhibition of IGF-1 receptor with PPP has been dem-
onstrated in a lot of cancers such as multiple myeloma [26], melanoma [28], breast 
cancer [29], and glioblastoma cells [30]. PPP inhibited Akt activation and suppressed 
cell proliferation in group 1 and group 2 NB cell lines but less in group 3 NB cell lines 
[10]. Elevation of ERK phosphorylation was only observed in group 1 NB cell lines 
[10]. U0126 is a MEK inhibitor effectively suppressed ERK phosphorylation, U0126 
(2.5 μM) did not suppress cell proliferation induced by IGF-1, IGF-2, or insulin in 
group 1 and group 2 NB cell lines [10]. In groups 1 and 2 NB cell lines, IGF-1 recep-
tor/PI3K/Akt pathway is critical for cell proliferation. Although IGF-1, IGF-2, and 
insulin activated Akt in group 3 NB cell line, cell proliferation was not increased in 
RPMI1640. This suggests that the activation of IGF-1R/Akt pathway is insufficient 
for cell proliferation [10]. Since IGF-1 and IGF-2 regulate apoptosis [31] and cell 
cycle progression [32], activation of caspase 3 and PARP was examined in NB cell 
lines. In group 1 NB cell lines, caspase 3 and PARP were not cleaved in RPMI1640 
[10]. In group 2 NB cell lines, caspase 3 and PARP were cleaved in RPMI1640, and 
the cleavage of caspase 3 was suppressed by addition of IGF-1, IGF-2, and insulin 
[10]. In group 3 NB cell lines, cleavages of caspase 3 and PARP were observed in 
RPMI1640 [10]. However, they were not suppressed by IGF-1, IGF-2, and insulin, 
even though Akt activation was upregulated by IGF-1, IGF-2, and insulin [10]. Since 
PPP induced G2/M arrest and apoptosis by inhibiting IGF-1 receptor [26, 33], cell 
cycle phase distribution in NB cells was examined in the presence of PPP. PPP treat-
ment (2.5 μM) for 12 hours increased the G2/M fraction and shifted cell cycle profile 
from G0-G1 dominant to G2/M dominant in group 1 and group 2 NB cell lines [10]. 
However, group 3 NB cell lines did not show G2/M arrest and the G0/G1 fraction was 
not affected [10]. Furthermore, cyclin B1, a marker protein of G2/M phase of cell 
cycle, was upregulated, and cyclin D1, a marker protein of G0/G1, synchronously 
declined in group 1 and group 2 NB cell lines [10]. However, accumulation of cyclin 
B1 and decline of cyclin D1 were not observed in group 3 NB cell lines [10]. This may 
be explained by the insensitiveness of group 3 cell lines to PPP-induced G2/M arrest.
4.  Impairment of Akt activation and cell proliferation in NB by Akt 
inhibitor, MK2006
MK2206 selectively inhibits AKT and has potency against Akt1 and Akt2 isoforms 
than Akt3. In pediatric solid tumors, MK2206 is effective in vitro and in vivo [34, 35]. 
In clinical trials, stable disease was observed in different kinds of cancers [36, 37]. Our 
results also suggested that MK2206 (2.5 μM) completely inhibited Akt phosphoryla-
tion and cell proliferation in NB cell lines [10]. Furthermore, MK2206 also impaired 
the cell proliferation induced by exogenous IGF and insulin in NB cell lines [10].
5. Inhibition of NB cell proliferation by mTOR inhibitor
The PI3K/Akt/mTOR signaling cascade is one of the most important intracellular 
pathways, which is frequently activated in diverse cancers [38, 39]. The PI3K/Akt/
mTOR pathway can be activated by transmembrane tyrosine kinase growth factor 
receptors, such as IGF-1 receptor, fibroblast growth factor receptors, ErbB family 
receptors, and others [40, 41]. Both mTOR S2448 and mTOR S2481 were extensively 
phosphorylated in NB cell lines [13]. Cell proliferation of NB cell lines was inhibited 
by AZD8055, a potent dual mTORC1-mTORC2 inhibitor [13]. According to the 
IC50, the NB cell lines were divided into two groups, sensitive to AZD8055 group 
(IC50 < 0.5 μM) and insensitive to AZD8055 group (IC50 > 0.5 μM) [13]. We also found 
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that insensitive group showed lower mTOR (p < 0.001) expression and lower activity 
of mTOR complex 1 (p = 0.013) and mTOR complex 2 (p = 0.023) [13]. Cell cycle 
distribution analysis of NB cell lines was performed by flow cytometry. Cell cycle was 
affected with an increase in G0/G1 phase in dose-dependent manner of AZD8055 [13]. 
Western blotting analysis revealed that Cyclin D1 and Cyclin D3 were downregulated 
in AZD8055-treated NB cells [13]. AZD8055 inhibited both mTOR S2448 and mTOR 
S2481 phosphorylation significantly in a concentration-dependent manner [13]. 
Phosphorylation of downstream targets of mTOR complex 1, P70S6K T389 and 4E-BP1 
S65, was also inhibited by AZD8055 treatment [13]. AZD8055 inhibited mTOR com-
plex 2 substrates, Akt S473 and Akt T308 [13]. Although phosphorylation of Akt S473 
was persistently inhibited in response to AZD8055 treatment, phosphorylation of Akt 
at the T308 site was inhibited for only 3–6 hours. These results indicate that AZD8055 
inhibits mTOR activity and its downstream proteins in vitro in NB cells. Interestingly, 
NB cell lines were induced autophagy by AZD8055 treatment via downregulation of 
Akt/mTOR signaling pathway [13]. Autophagy inhibitor, 3-methyladenine, treatment 
resulted in a significant decrease of the AZD8055-induced apoptosis [13]. These results 
suggest that AZD8055 inhibited cell growth and induced cell cycle arrest, autophagy, 
and apoptosis in NB cells. Moreover, NB tumor growth in athymic nude mice was 
significantly inhibited by AZD8055 without toxicity [13]. Taken together, our results 
highlight that mTOR is a promising target for NB treatment. AZD8055 might be 
investigated for treatment of patients with advanced and refractory NB.
6. AZD8055 treatment in combination with MEK/ERK inhibitor
The problem that will plague single-target drugs is the cancer’s ability to acti-
vate alternative survival pathways leading to drug resistance and toxicity even in 
the multimodality setting. In addition, activation of multiple signaling pathways 
effectively causes cancer cell proliferation and survival. For example, RAS and 
PI3KCA are concurrently activated in melanoma, lung, and colorectal cancers 
[42–44]. These results suggested that combination therapies targeted on multiple 
signaling pathways could be more effective than targeting either pathway alone. 
Although AZD8055 is a promising drug in NB treatment [13], AZD8055-resistant 
NB sublines were acquired by prolonged stepwise exposure. After incubation with 
AZD8055 for 4–12 weeks, two acquired AZD8055-resistant sublines proliferated 
stably in RPMI1640 plus 10% FBS medium in the presence of AZD8055 (3 μM) [12]. 
The AZD8055-resistant sublines exhibited marked resistance to AZD8055 compared 
to the parent cells, and IC50 of the resistant sublines was 60–100 times higher than 
the parent NB cell lines [12]. By cell cycle analysis, accumulation of S phase was 
observed, and cyclin D3 and CDK4 were upregulated in AZD8055-resistant sublines 
[12]. Although AZD8055 treatment inhibited MEK/ERK activation in parent cells, 
MEK/ERK phosphorylation was continued despite AZD8055 treatment in resistant 
cells [12]. The combination therapy of AZD8055 and MEK/ERK inhibitor U0126 
significantly inhibited cell proliferation compared to U0126 monotherapy [12], sug-
gesting that combination therapy can overcome AZD8055 resistance. Furthermore, 
in athymic mice model, AZD8055 and U0126 co-treatment was more efficient to 
suppress resistant NB tumor growth compared to U0126 monotherapy [12].
7. MK2206 treatment in combination with PDK1 inhibitor
MK2206 treatment induced a dose-dependent inhibition of cell proliferation, 
with IC50 ranging from 1.22 to 4.35 μM in NB cell lines [11]. MK2206-resistant cells 
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were induced by stepwise escalation of MK-2206 exposure (4–12 weeks) [11]. These 
cells proliferated in RPMI1640 plus 10% FBS medium in the presence of MK2206 
(5 μM), while cell death was induced in parent cells [11]. IC50 of the resistant 
cell lines was 6–7 times higher than the parent NB cell lines [11]. Small-molecule 
GSK2334470 selectively inhibits 3-phosphoinositide-dependent protein kinase 1 
(PDK1) with low concentration but does not suppress the activity of other protein 
kinases at higher concentrations [45]. Although GSK2334470 attenuated cell prolif-
eration in both parent cells and MK2206-resistant sublines, IC50 of GSK2334470 in 
resistant sublines was lower than that of parent cell lines [11]. GSK2334470 induced 
G0-G1 accumulation of cell cycle phase distribution in parent cell lines [11]. In 
MK2206-resistant sublines, G0-G1 accumulation induced by GSK2334470 was 
higher than parent cell lines [11].
8. Effect of NB MYCN status on susceptibility to AZD8055
Amplification of the MYCN oncogene is the most powerful single predictor 
of adverse outcome of NB [46]. MYCN amplification is observed in about 20% 
of all NB patients and is usually associated with fatal outcome of the disease [47]. 
Schramm et al. demonstrated transcriptomal upregulation of mTOR-related 
genes by MYCN [48]. MYCN-driven NB in mice displayed activation of the mTOR 
pathway on the protein level, and activation of MYCN in NB cells resulted in high 
sensitivity toward mTOR inhibition [48]. Therefore, it is examined whether MYCN 
Figure 1. 
Effect of MYCN status on susceptibility to AZD8055. (A) MYCN gene in tested 12 NB cell lines. MYCN 
status was defined as previously [53]. No alteration: cells with two MYCN signals and two CEP2 signals; 
amplification: the number of MYCN signals is at least 10 copies greater than the control probe signals; loss/
imbalance: presence of at least two MYCN signals and increased CEP2 signals; gain: the number of MYCN 
signals is 1–9 copies more than CEP2 signals. (B) Fifteen NB cell lines were treated with AZD8055 at different 
concentrations in RPMI1640 + 10% FBS. Cell growth was evaluated as cell numbers at 72 hours. Data 
are expressed as the mean ± SD. IC50 (half maximal inhibitory concentration) of the 15 NB cell lines was 
calculated depending on the MTT results.
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status of NB cell lines affects susceptibility to AZD8055. Using fluorescence in situ  
hybridization (FISH), we observed MYCN amplification in all investigated nuclei of 
NB19, IMR32, TGW, OZAWA, LAN-1, SMS-KAN, and SCMC-N4 cell lines (Figure 1A).  
As shown in Figure 1A, MYCN amplification was not observed in INDEN (loss/
imbalance), SK-N-SH (gain), KP-N-SI (loss/imbalance), KP-N-SIFA (gain), and 
SJ-N-KP (loss/imbalance). As shown in Figure 1B, the relationship between MYCN 
status and susceptibility to AZD8055 was not found.
9. ALK as a therapeutic target in NB
Constitutive activation of the ALK receptor tyrosine kinase by mutation or 
translocation appears to contribute to the malignant phenotype of several cancers, 
including NB, making it a potentially therapeutic target [49]. Both wild type ALK 
and the F1174L-mutated ALK upregulate MYCN expression [50], and these two 
genes lead to constitutive phosphorylation of ALK and of downstream signaling 
molecules, PI3K/AKT/mTOR, that are critical for cell proliferation and survival 
[51]. ALKF1174L cosegregates with MYCN amplification in patients, and this com-
bination is associated with a particularly poor prognosis, as shown by the fatal 
outcome of 9 of 10 children with ALKF1174L/MYCN-amplified tumors [52]. Targeting 
ALK with PI3K/Akt/mTOR inhibitors may inhibit cell growth in tumor lines with 
concomitant MYCN amplification.
10. Conclusions
NB cell lines can be categorized into three groups by the patterns of IGF-1R/
Akt pathway response. PPP, MK2206, and AZD8055 showed significant antitumor 
effect in NB cells. Our current results highlight the potential of IGF-1R/PI3K/
Akt/mTOR pathway as a promising target for NB treatment. PPP, MK2206, and 
AZD8055 should be further investigated for NB treatment in clinical trials.
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